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THE PHARMACEUTICAL INDUSTRY
Jaqueline J. Wickersham
The 1992 presidential campaign turned the nation's attention to a number
of issues. but none was more controversial than the need for health care reform.
As a result of the 1994 election, it appears that President Clinton's proposed
health care plan will not gather the support necessary to become law. This
does not mean that reforms will fail: it merely means that change will continue
as it has for the past ten years. fueled by the people footing the majority
of the nation's health costs: employers.1 As of 1993, employers were paying
more than one-third of all medical bills in the United States.2 This is not
to say that government has no role in this metamorphosis. Since state and
federal governments employ large numbers of people, they, too, have a signicant
interest in cost controls. In addition, state and federal governments share the
costs of Medicaid, and the federal government is responsible for Medicare.3
The twin focus of health care reform is to control costs while main-
taining quality care.4 There is little doubt that a country forced to choose
between the two goals will prioritize the former.5 In order to maximize savings,
those involved with various aspects of health care are integrating, so that the
1Calif~o America's Health Care Revolution: Who Lives? Who Dies? Who Pays? in
Curran, Hall and Kaye 678 (Simon & Schuster, 1986).
2Robert Pear, Health Care Costs Up Sharply Again Posing New Threat, N.Y. TIMES,
January 4, 1994.
3Janies F. Blwnstein, Health care Reform: The Policy Context, 29 WAKE FOREST L.
REV., 16, 30-32 (1994).
4john K Inglehart, Health Policy Report The American Health Care System Managed Care,
327 THE NEW ENGLAND JOURNAL OF MEDICINE, 742, 746 (1992).
5Id. at 743.
1actual providers are merging with hospitals and management systems.6 The
form ultimately assumed depends on the particular plan, but the basic patterns
are health maintenance organizations (HMO), preferred provider oroanizations
(PPO'D, and preferred service organizations (P50).7
Traditionally doctors, patients, and insurance companies were at
odds. Normally doctors worked without the supervision of employers, the par-
ties actually funding treatment of patients. By 1987, insured patients paid less
than 26 cents for every dollar spent on their health care, and this gure has
only fallen.8 This came about for a multitude of reasons, one of which is the
structure of the income tax system.9
Pharmaceuticals account for only seven percent of all medical ex-
penses.10 Managed care is designed to align doctors' interests with those of
payors by rewarding them for cost-eective treatments.11 Under this system
doctors join forces either as employees or partners in a managed care program
(generically referred to as an HMO throughout this paper).12 Treatments pre-
scribed by the doctors are monitored so as to reward those doctors who work in
the most ecient manner.13 One simple cost saving step is to reduce the num-
ber of drugs prescribed, or to limit those which are covered or even available.
6Id. at 745.
7'Id.
8John K. Iglehart, Health Policy Report The Amencan Health Care System Introduction,
326 THE NEW ENGLAND JOURNAL OF MEDICINE, 962,963(1992)
9Blumstern, at 21.
10Michael A. Weber, Impact on the Pharmaceutical Industry of Changes in the Amencan
Health Care System: A Physician's Perspective, 24 SETON HALL L. REV., 1290, 1322
(1994).
11Iglehart, Managed Care at 742.
12k1 at 744-45.
13Id:at 746.
2This could have a profound eect on the pharmaceutical industry.
Economists and experts are already apprehensive about the that
eects this will have on the industry. Pharmaceutical companies have begun to
expand their repertoires of marketing techniques for existing drugs while lim-
iting plans for future research and development. 14Like other branches of the
medical community they are cutting back on expensive services to focus on the
more basic.15 However, drug manufacturers are not like the rest of the medical
community. While other branches of medicine similarly provide innovative tech-
niques for treatment of disease, none are as potentially cost eective as drugs.
16
The primary expense of drugs lies in their development. Out of an
average of 5000 potentially marketable combinations, only one will actually be
safe and eective enough to be marketed.17 Manufacturers are required to incur
signicant expense by carrying out extensive testing prior to release of a new
pharmaceutical.18 This is the primary reason that drugs are often prohibitively
expensive. If the market for drugs were to change, so that HMOs restricted drug
availability on the basis of price, manufacturers would not have the capability to
provide the $359,000,000 (in 1990 dollars) required to get a drug to consumers.
14Henrv Grabowski, Health Reform and Pharmaceutical Innovation, 24 SE~ON HALL L.
REV., 1221, 1241 (1994).
15Weber,at 1293.
16 ~There are many costs inherent in medical procedures. They include everything from time
lost trom work to the labor resources consumed when a patient sees a doctor to the costs of
the materials used in the actual procedure. Once a drug treatment is prescribed, on the other
hand, a patient can be easily monitorred by a nurse. Tracking the patient requires minimal
resources.
17Weber at 1300.
18Grabowski, at 1236
319
This may not seem to be of critical importance to HMOs. After
all, the existing market seems to be saturated with pharmaceuticals, and the
purpose of an HMO is to prevent the need for medical treatment by encouraging
subscribers to adopt healthier lifestyles and take a more active role in maintain-
ing their own health.20 This would not, however, eliminate all need for medical
care, and drugs are often a far cheaper method of treatment than surgery. In
a system involving limited access to costly and complicated treatments such as
surgery, drugs are an attractive alternative.
In order for innovation to continue, however, managed care systems
must be willing to either pay the prices currently charged by drug manufacturers
or there must be changes in the structure of research funding. It is to the possible
changes that attention will be directed.
I.MERGER OF PHARMACEUTICAL COMPANIES INTO HMOS
One possibility would entail a merger of large pharmaceutical com-
panies into individual HMOs.21 This is an attractive proposition in practical
terms for a number of reasons. For such a transaction to be benecial, however,
the pharmaceutical company would have to be large enough to supply the HMO
with essentially all of its drug needs. In addition, with the expense involved in
a pharmaceutical company, only large HMOs could support this sort of drug
habit.
This is an interesting proposition for a number of reasons. As tort
19k1.
20Enthoven, at 836-37.
21c4, Weber.
4liability now stands drug companies are liable for many of the injuries caused by
their products, even when the products are properly tested and have obtained
FDA approval.22 The federal government has taken some steps to limit liability
in the form of the National Childhood Vaccine Injury Act, but this is minimal
protection in relation to the number of claims with which drug manufacturers
are threatened with on a regular basis.23
Proponents of managed care have recognized the necessity of con-
trolling liability. There are several dierent means of by which plans may address
this issue. Some plans may simply limit the amount that their subscribers can
receive for an injury. Others advocate moving to a system of enterprise liability
in which individuals are not personally liable to the injured party; instead, the
corporation handles the claim.24 Within such a scheme a corporation would
have the right, and the responsibility, to review employee performance and dis-
cipline or dismiss workers as necessary. This sort of insurance shield could be
very attractive to pharmaceutical companies.
There would be some drawbacks, however. In order to be a part of
a managed care system the companies would lose some of their independence by
becoming part of a larger system. More importantly, since the focus of managed
care is on the allocation of resources, there is the potential that research budgets
will be slashed. In the alternative, a company would have a guaranteed market.
It would also have easy access to doctors who could be required to run tests of
22William M. Sage, Drug Product Liability and Health Care Delivery Systems, 40 STAN.
L REV., 989, 989 ( l9~).
23Huu and Merrill, Food and Drug Law, 718-719 (1991).
24Darling v. Charleston Coin,nuniri Memorial Hospital,383 U.S. 946; 86 S.Ct. 1204 (1966).
5their new concoctions. This would reduce some of the administrative costs of
nal rounds of drug testing.25 With consumers provided, rms could spend far
less on marketing. This means that they could discontinue the advertisements
that are now a regular part of magazines, which would entail substantial cost
savings, as evidenced by gures indicating that pharmaceutical corporations
currently spend almost as much on drug promotion as medical schools spend
on all educational activities.26 In addition, it would no longer be necessary to
entice doctors into nding out about a new drug by sponsoring symposia and
other perks. Doctor education on the use of new pharmaceuticals could become
a regular part of a doctor's job, as, for instance, training could be done during
regular sta meetings. However, if the individual health care system chose to
handle it, this could become a contractual rather than optional requirement.
One of the main diculties in developing new drugs is that the
process is extremely expensive, and even with the 1964 Drug Price Competition
and Patent Term Restoration Act, which extends the length of a patent term
by allowing the developer to add to the 17 year patent term the time necessary
for testing, patent turnover is relatively high in relation to the amount spent
in bringing a drug to the market.27 Further, the current system is rife with
freeriders and copycat drugs. As the system is presently organized, a manufac-
turer is faced with the risk of investing in a new drug, only to be undercut by
a competitor or a generic drug long before the manufacturer has recaptured its
costs. Because a competitor need only follow an abbreviated process to get FDA
25C.f., Sage
26at 1016.
27at 1023.
6approval, they may capture a large share of the market simply because they can
sell a drug for less.28 It has been projected that by the year 2000 generic drugs
could account for sixty-ve percent of all new prescription drugs.29 If a drug
company was part of an HMO it would be protected from these changes. Be-
cause manufacturers could be guaranteed a percentage of the market they would
be willing to invest in developing a drug and settle for charging less. This results
in a period of recovery which may be longer, but eventual recovery is virtually
certain.
One diculty lies in convincing HMOs that it is advantageous for
them to make this sort of investment. That will depend, in part, on the be-
havior of the pharmaceutical industry. If drug manufacturers cooperate to keep
prices high, HMOs may well nd it in their best interests to acquire a drug
manufacturer and institute some sort of supply system. However, if the drug
companies merely compete with one another, as is now occurring, drug prices
will most likely be driven down.30 It then becomes a question of whether drug
prices will sink far enough for HMOs to decide that it is more cost eective to
contract with the companies than to actually bring them inside the system.
If an HMO is interested in utilizing drugs, and desires continued
innovation, it may opt for a halfway point such as subsidizing research. This is
currently the position taken by the federal government.31 If the HMO chooses
merely to subsidize, it will have far less control over the company's actions. This
28Id. at 1242.
29Id.
30Id. at 124t.
31Weber,at 1303.
7is very important. Part of the cost saving that should occur under managed care
will occur because corporations will simply choose not to treat some conditions,
or to limit the treatments available. Rare conditions will likely receive lower
priority throughout the HMO than common ones, whereas drug research by
independent drug companies currently focuses on discovery of pharmaceutical
solutions for basically anything that insurance will pay for. In addition, by
investing in an actual manufacturer, HMOs, in the advent of a new drug, would
be able to market the substance to other HMOs at an inated price. bringing
additional prots to the original HMO. This advantage could tip the scale in
favor of acquiring a pharmaceutical corporation of its own.
Belonging to an HMO could potentially reduce the costs of the
latter stages of drug research for pharmaceutical companies. One characteristic
of managed care is extremely good record keeping. This is necessary in order
for administrators to monitor doctors' work. It would not be unusual to require
extensive recordkeeping for each patient, as is necessary when running drug
trials. Even more to the point, this could be made a contractual duty.32 An
HMO would likely have access to many kinds of specialists, and would have
much information available about the practices of specic physicians so that
any biases they might have that could prejudice an experiment could be more
easily identied.
Access to specialists would, however, be more limited in HMOs.
This is a fundamental aspect of controlling costs. Because it would be more
32sf Sage.
8dicult to see a specialist, it is entirely possible that patients would be willing
to participate in drug trials in exchange for access to more specialized care than
might have otherwise been available for their condition. For example, a person
having chest pains might normally only have access to a general physician; but
if she were willing to try a new drug she might see a cardiologist. In such a case
the patient, HMO, and pharmaceutical company would benet, at least so long
as there were no adverse reactions.33
A managed care system is a risky proposition because, in part,
of federal regulation of trade and competition. This arrangement is unlikely,
however, to be a problem because it a vertical integration rather than horizontal.
The savings resulting from this arrangement stem not from a lack of competition
but from the nature of a monopsony, which uses its size to drive prices down.34
The focus of both the Sherman and Clayton Acts is on preventing the restraint
of competition between parties who are supposed to be in competition with one
another.35 In this case pharmaceutical companies are not supposed to compete
with doctors or insurance companies. The government will also take action
when a corporation has a monopoly on a good or service and refuses to make it
available on reasonable terms to anyone else.36
The McCarran-Ferguson Act may provide additional protection
from federal antitrust laws.37 It protects the business of insurance from an-
33cxf.. Sage
34Janct L. McDa,id, Antitrust Issues in Heath Care Reform, 43 DEPAUL L REV., 1045,
1058 (1994).
35Id: at 1059.
3611 at 1069.
37Id. at 1075-76.
9titrust laws so long as the corporation does not engage in boycotts, coercion or
intimidation.38 This law could poentially shelter HMOs from federal regulation,
though there may be complications if the HMO has subscribers in more than
one state, which will probably be the case if the HMO is big enough to support
a pharmaceutical manufacturer.
The system as envisioned can easily sidestep these pitfalls. The only
real problem arises if an 1-IMO tries to use ownership of a drug as a selling point
of a managed care package within its own companions while making the drug
inaccessible for members of other HMOs. Such limitations would be unlikely,
however, since an HMO would likely earn larger prots by pedaling a drug to
outside HMOs, so economic motivations encourage making the drug available.
Therefore, the antitrust law should pose few problems.
II.HORIZONTAL SYSTEMS
No HMOs have taken steps to acquire a pharmaceutical company
as of yet. Drug manufacturers, suppliers, and pharmacies are beginning to
form their own organizations modeled after managed care systems. The most
recent of these is the merger of Merck and a distribution corporation, Medco.39
This is a smaller form of the merger proposed above. It involves fewer health
care providers, which may make it less expensive because there will be fewer
administrative costs to forming the alliance. Because this is a vertical system
there should be few problems with antitrust laws for the reasons listed above.
These organizations typically contract with HMOs and other health
38Id. at 1075.
39Weber, at 1304.
10care providers to supply pharmaceuticals.40 One advantage, of course, is that
there are fewer overall service charges because a middleman has been cut out
of the process. It is also less costly to administer, if done properly, because
many of the functions typically required by both corporations, such as moving
the pharmaceuticals, tracking the drugs, and general administration, can now
be performed by just one. In addition, when the manufacturer and distributor
work independently they both have an interest in advertising their products to
the medical community and public. This leads to ineciencies as each tries
to reach the public in order to ensure a market. In a merged system this can
be handled by one department so that there will not be the repetition that
currently exists.
Another trend within the pharmaceutical industry is for indepen-
dent pharmacies to join forces. This form of organization has less potential
than that of a manufacturer and distributor for a number of reasons. The
most important problem with this form is that it is horizontal, which leads to
problems with antitrust regulations.41 This is exactly the sort of system that
fosters price controls, even when that was not the original purpose, because
businesses that would normally be competitors are allying. In addition, many
of the administrative eciencies that are present in a vertical alliance will not
be present here. The independent pharmacies will still have to maintain most
of their normal sta. The one important economy of scale would be that bulk
purchases of medications would be possible, rather than each pharmacy acting
405ee. e.g. Jeerson County Pharamaceutical Association,Inc. v. Abbott Laboratories et
al., 460 U.S. 150(t983).
41Id.
11as an independent buyer.
Drug manufacturers face more liability in arrangements of this sort.
If a manufacturer is part of an HMO, it is in the HMO's best interests to limit
the liability of the pharmaceutical corporation. When they have not joined
forces, however, the manufacturer is merely a target for plaintis whose claims
against an HMO for negligent care may be limited or barred. Because drug
treatments are often less expensive than surgery, there is economic motivation
for an HMO to use new drugs, which may not be fully understood, to try to
treat a patient, rather than conventional surgery.42 The patient may sue the
drug manufacturer for any adverse reactions, especially if the tort climate is
similar to that existing today, in which new forms of liability are invented every
day.43
The HMOs may self-regulate to some extent, simply because they
must treat any patients who experience adverse drug reactions.44 This will
temper any desire to conduct outlandish experimentation. However, doctors
are permitted, by law, to prescribe any pharmaceutical, and they will be under
much pressure to reduce costs.45 This combination of pressures will result in
novel uses of drugs. It is dicult to predict the extent of the use, because much
of it will probably be surreptitious, unless the drug is clearly eective.
Ill.PHARMACEUTICAL COMPANIES AS INDEPENDENT EN-
TITIES
42C.f. Sage at 989.
43Id. at 1010.
44Id. at 1005.
45Id. at 1021.
12If the nation continues its move to managed care without actively
incorporating pharmaceutical companies into the system the availability of new
drugs will be severely limited unless HMOs are willing to pay prices as they now
stand. This is highly unlikely. Even now the pharmaceutical industry is making
changes, trying to make itself more attractive to the cost-conscious consumer,
the HMO.46 The marketing strategies used with ACE inhibitor cardiovascular
medicines are a good example.47 Unfortunately, many of these changes must be
announced, raising the costs of advertising. Even so, the short term eects will
be very benecial for consumers, who will save money. The long term eects
are less clear.
There is an established market for drugs such as penicillin and
insulin. Production of those staples should continue unhindered. Prices on the
drugs may fall as HMOs force drug manufacturers to charge a price closer to
the actual production costs of the substance. There may be a slight fall in the
amount consumed because of a tendency among HMOs to regulate prescription
through drug utilization reviews and drug formularies.48 Depending on how
much over medication now occurs this may or may not aect the industry. As
prices drop for these staples because of the eects of competition, manufacturers
must be resigned to smaller prots, and may have to reallocate funds in order
to meet the general costs of doing business.
Pharmaceutical companies may also face a risk of higher amounts
of litigation. One of the components of managed care is enterprise liability.
46Gm4'sIcj at 1242-43.
47id.
48Id. at 1241. Formularies are lists of drugs which the HMO allows practioners to prescribe.
13Most HMOs limit the amounts available to patients through contractual liability
limitations. With large recoveries barred by contract, injured plaintis will be
turning an eye towards pharmaceutical companies as the new deep pocket.49
Even if most of the suits brought are unsuccessful, the costs of litigation will be
high. In addition, there is the risk that companies will settle merely to avoid the
costs of litigation.50 This could lead to additional trouble in the form of strike
suits. As discussed above, plaintis may also attack companies for doctors'
inappropriate use of medications.51
There is no doubt that drug manufacturers are a target of litigation
today. One need only look the reasons for the National Childhood Vaccine
Injury Act to see that the costs are currently devastating to corporations.52
As the system now stands, there are many dierent targets. A pharmaceutical
company is not necessarily the most fruitful entity to sue. In the future, it may
be the only one.
Faced with the possibility of even more liability, and coping with
a shortage of consumers willing to pay the high prices necessary to make de-
veloping a new drug a reasonable proposition, the drug industry will severely
reduce the amount of research undertaken in the future. The drugs most likely
to be lost are the exotic drugs which are necessary for treating rare diseases
such as multiple sclerosis. In addition, if 1-IMOs, to save costs, refuse to allow
49C.f., Sage.
50C.f., W. Kip Viscusi, et al, A Statistical Prole of Pharmaceutical Industry Uability,
1976-1989, 24 SETON HALL L. REV., 1418, 1436(1994).
511) at 1012.
52Viscusi, at 1425-28. In 1986 Merrell Dow lost 11 cases, and ~id an average of $7.1 million
to each plainti. In 1985 the median pharmaceutical award was $10.5 million.
14speculative treatment of diseases such as AIDS which are currently recognized
as incurable, and instead limit the patients to maintenance care, experimenta-
tion on to invent curatives will cease. It makes little economic sense to search
for a cure for a condition which kills one's consumer. A pure economic analysis
would indicate that manufacturers will continue to search for substances which
treat disorders which are serious enough to require continuous care and are not
curable, but are also not fatal. A good example of such a condition is a seizure
disorder.
Unless HMOs are willing to actively subsidize research, such activ-
ity will continue in a limited fashion. As was argued earlier, the development of
new pharmaceuticals could be cost ecient in the long term. However, many
HMOs may view this dierently. If a drug does not exist, there will be far less
patient demand for the substance. If a treatment is available and the HMO is
simply denying its patients coverage, patient outcry is a likely response. There-
fore, it is probable that if the industry continues to be comprised of separate
units it is unlikely that HMOs will interfere with the status quo except in in-
direct manners such as refusing to pay the prices drug manufacturers are now
asking.
IV.GOVERNMENT
It now appears that government mandated health care reform is not
going to occur during this presidency. This does not mean that the government
is unconcerned with the reforms occurring as a result of market inuences.
Federal and state governments have an interest in the pharmaceutical industry
15for a number of dierent reasons. The federal government has more direct
authority over drug manufacturers because regulation of the substances has been
done primarily through federal law and the institution of the FDA. In addition,
antitrust laws are also federal in origin. However, tort law is generated by the
states. Examining the industry from this vantage point, though, the problem
looks no more complicated than any issue arising from a national corporation.
State and federal governments actively take responsibility for the
welfare of American citizens. This takes the form of regulations promulgated
by Congress requiring that foods and drugs meet certain standards. It is also
evidenced by vaccine laws and public health programs. If no one else is available
to provide health care for the needy, the government is supposed to do so. To
meet these needs it established Medicaid. The government is also responsible
for the healthcare of the elderly through Medicare. As if that were not enough,
state and federal governments employ huge numbers of people, many of whom
they now insure.
People over the age of 65 are responsible for three times the con-
sumption of pharmaceuticals of that of people under 65 in the country today.53
They far outstrip any other age group in drug use. Drug treatment is prefer-
able to the options now available in many cases. For instance, it costs approxi-
mately two dollars per day to treat a patient for a heart condition using drugs.54
Surgery costs approximately $6OO0.55 Unless a person is expected to live for
53Michad 3. Barberi, Managed Prescription Drug Plans: Strategies, Trends, and Health
Care Reform, 6 BENEFITS LAW JOURNAL, 419,420(1993)
54Weber, at 1308.
55ID.
16many years, it is far more cost eective to treat them with drugs, especially
when the risks of surgery are factored into the equation. While Medicare cur-
rently covers only a small amount of the actual drugs prescribed, this may soon
change.56
Even if Medicare does not directly cover the costs of medications,
there are indirect costs to the program. These come in the form of patients
opting for surgical treatments instead of drugs, because Medicare will cover the
costs of the procedure. In addition, Medicare is responsible for any hospitaliza-
tion that is a result of an adverse drug reaction or a condition stemming from
the failure to take medications. Many elderly people cannot aord treatments.
In addition, all medications prescribed to people receiving Medicaid are publicly
funded.
As noted earlier, the private sector pays for approximately one-
third of all medical care. State and federal governments pay for a majority of
the rest. Medicare and Medicaid make state and federal governments especially
interested in pharmaceuticals because of the high amount of drug usage by
these patients, who tend to have more health problems and be more vulnerable
in general. Even if health care reform is privatized, the government must take an
active role in shaping the future of drug research. As the single largest consumer
of health care, it has the ability to do so.
V.CONCLUSION
The forms proposed above are sketches of what is possible. The
56Naali Bendavid, Health-Care Reform: The Clash of Interests and Agendas, LEGAL
TIMES, Oct. II, 1993, S23, S33
17system that actually results, no matter which pattern it follows, will almost
undoubtedly vary in the details. The only open question is how this will this
aect the consumer. It seems clear that patient choice will be more limited. This
will occur not only because HMOs will limit the availability of drugs, but because
it is too costly to do research. More importantly, much of the truly innovative
work is being done by small bioengineenng companies which lack the capacity
to produce more than a few products. It is not worthwhile for HMOs to acquire
these small companies. They may be able to function in a system organized as
distributors and manufacturers, but that reduces the economies of scale which
makes the structure worthwhile in the rst place. If pharmaceutical companies
remain independent in the face of managed care, these small corporations will
be at risk because of diculties in nding a market for their drugs. In addition,
there may be increased risks of liability.
Pharmaceutical corporations may be saved by the existence of a
world market. Marketing new drugs in other countries with fewer regulations
might allow cheaper development, at least in the later stages, of new drugs so
long as the manufacturers are willing to collect data regarding the outcomes
of such usage. The FDA would also have to be willing to accept those tests
without requiring them to be replicated as clinical studies in the United States.
At this point in time this is not a viable option. If changes in the medical
community continue, though, consumers, producers, and government regulators
may be willing to make the compromises necessary to allow this to work.
If continued research is desirable, it must be subsidized. First, how-
18ever, society must decide whether it wants research to continue at the breakneck
speed at which it has occurred over the last fteen years.57 Some might argue
that this is in fact a waste of resources and that the money might be better
spent on education or another social cause. Further, there is a problem recog-
nized by the medical community. It has been named Maxwell's Paradox. It is
an acknowledgment that the more that is spent on medical care now, the more
money will be necessary in the future.
If people desire continued innovations, they must make a clear
statement of their wishes. The government has the ability, outside of its legisla-
tive functions, as a consumer, to stimulate continual development. In addition,
research could be stimulated through grants to hospitals and even by tax re-
form. Before any of this occurs, however, people must make some hard decisions
about priorities.
57Bendavid, at S33. During the 1980s pharmaceutical corporations raised their pnces by
more than twice the rate of ination. This has not gone unnoticed, so that now reformers
turn their attention to the industry.
19